BICYCLIC HETEROCYCLIC SPIRO COMPOUNDS

There are provided certain bicyclic heterocyclic compounds that act as M1 muscarinic receptor modulators. Compositions containing these compounds and their use are also disclosed. 2. A compound according to wherein R is methyl.3. A compound according to wherein p and n are each 1.58-. (canceled)9. A compound according to wherein Ris methyl.10. A compound according to wherein Ris H.11. A compound according to wherein Rand Rare each H.12. A compound according to wherein Ris H.13. A compound according to any wherein Y is S.14. A compound according to wherein Y is O.15. A compound according to wherein Ris optionally substituted —C(O)—(C)-indol-3-yl.16. A compound according to wherein Ris selected from the group consisting of —C(O)—CH-indol-3-yl claim 15 , —C(O)—CHCH-indol-3-yl claim 15 , —C(O)—CHCHCH-indol-3-yl claim 15 , trans —C(O)—CH═CH-indol-3-yl and —C(O)—CH(NH)—CH-indol-3-yl.1720-. (canceled)22. A compound according to wherein Ris selected from the group consisting of —SO-4-fluorophenyl claim 1 , —C(O)CH(n-propyl) claim 1 , —C(O)-(4-hydroxy-3 claim 1 ,5-di-tertbutylphenyl) and —C(O)—CHCH.2325-. (canceled)27. A compound according to which is selected from the group consisting of (1-(2 claim 1 ,8-dimethyl-1-thia-3 claim 1 ,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one) claim 1 , (+)-(1-(2 claim 1 ,8-dimethyl-1-thia-3 claim 1 ,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one) claim 1 , (−)-(1-(2 claim 1 ,8-dimethyl-1-thia-3 claim 1 ,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one) claim 1 , 1-(2 claim 1 ,8-dimethyl-1-oxa-3 claim 1 ,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)-propan-1-one claim 1 , (+)-1-(2 claim 1 ,8-dimethyl-1-oxa-3 claim 1 ,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)-propan-1-one claim 1 , and (−)-1-(2 claim 1 ,8-dimethyl-1-oxa-3 claim 1 ,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)-propan-1-one.28. A pharmaceutical composition comprising the compound AF710B and a pharmaceutically acceptable carrier claim 1 , excipient ...

COMPOUNDS AND METHODS FOR USE IN THE TREATMENT OF MICROGLIA-MEDIATED DISORDERS

Provided are M1 muscarinic acetylcholine receptor (mAChR) agonists, for use in the treatment of a neurological or neurodegenerative disease by promoting microglia and/or macrophage viability and/or activation. Microglia and macrophage survival and activation are thereby achieved by increasing levels of sTREM2 released by microglia cells. In addition, pharmaceutical compositions and methods of preparing the same are described, which are suitable for the treatment or prevention of conditions or diseases that require microglia and/or macrophage modulation, as well as methods for monitoring treatments and enhancing microglia and/or macrophage survival and/or activation. 5. The compound for use according to any one of to , wherein promoting the cellular viability and/or activation of microglia cells and/or macrophages is achieved by administering the compound in an amount effective to increase the level of soluble triggering receptor expressed on myeloid cells 2 (sTREM2).6. The compound for use according to any one of to , wherein the subject to be treated is negative for a mutation that impairs the biological activity of sTREM2 and has at least one functional allele of the TREM2 encoding gene , respectively.7. The compound for use according to claim 6 , wherein the mutation is R47H or R62H in the amino acid sequence of TREM2.8. The compound for use according to any one of the to claim 6 , wherein the treatment comprises administering to the subject 1 mg to 100 mg of the compound claim 6 , preferably 10 mg to 50 mg.9. The compound for use according to any one of the to claim 6 , wherein the compound is administered as oral solution or oral pill.10. The compound for use according to any one of to claim 6 , wherein the disease or condition is selected from the group consisting of brain amyloid-mediated disorders; GSK3β-mediated disorders; abnormalities in Wnt-signaling; TREM2-mediated disorders; tauopathies; a tau protein hyperphosphorylation-mediated damage claim 6 , ...

Crystalline polymorphs of a muscarinic acetylcholine receptor agonist

Provided are novel crystalline forms of a spiro-compound which acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are described which have favorable properties in pharmaceutical manufacture. Also provided are methods to prepare said crystalline polymorphs, and to convert them into each other as well as methods for preparing medicaments containing the same which are suitable for use in the treatment of diseases and disorders that respond to modulation of the muscarinic acetylcholine receptor.

CRYSTALLINE POLYMORPHS OF A MUSCARINIC ACETYLCHOLINE RECEPTOR AGONIST

Provided are novel crystalline forms of a spiro-compound which acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are described which have favorable properties in pharmaceutical manufacture. Also provided are methods to prepare said crystalline polymorphs, and to convert them into each other as well as methods for preparing medicaments containing the same which are suitable for use in the treatment of diseases and disorders that respond to modulation of the muscarinic acetylcholine receptor. 115-. (canceled)17. The method of claim 16 , wherein{'sub': 'α', '(a) the X-ray powder diffraction pattern contains at least two, three or all of the following 2-theta values as measured using CuK radiation: 8.8, 12.30, 17.30, 17.50, 17.80 and 23.0;'}{'sub': 'α', '(b) the X-ray powder diffraction pattern also contains at least one of the following 2-theta values as measured using CuK radiation: 12.3, 19.9, 21.6, 24.5, 26.3 and 31.6;'}(c) the X-ray powder diffraction pattern is substantially free of peaks having 2-theta values in the range of from 10.8-11.8;{'sub': 'α', '(d) the X-ray powder diffraction pattern contains at least one of the following 2-theta values as measured using CuK radiation: 12.2, 17.3, 19.9, 21.6, 24.5, 26.3 and 31.6, and wherein said X-ray powder diffraction is substantially free of peaks having 2-theta values in the range of from 10.8-11.8;'}{'sub': 'α', '(e) the X-ray powder diffraction pattern contains at least two, three, four, five or all of the following 2-theta values as measured using CuK radiation 12.2, 17.3, 17.5, 19.9, 21.6, 24.5, 26.3 and 31.2;'}{'sup': '13', '(f) the C solid-state NMR of the crystalline form contains resonances having at least two, three, four or all of the following chemical shift values as expressed in ppm relative to TMS: 67.56, 54.60, 41.49, 30.70 and 13.77;'}{'sup': '13', '(g) the C solid-state NMR of the ...

Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs

Bicyclic heterocyclic spiro compounds

There are disclosed bicyclic heterocyclic spiro compounds; pharmaceutical compositions comprising these compounds; and methods for the treatment in a mammal of diseases and conditions which are susceptible to modulation of the M1 muscarinic receptor, including Alzheimer's disease, insulin resistance syndrome and type 2 diabetes. Other embodiments are also disclosed.

Tritium labelled n-mustard type compounds and a process for their production

NOVEL TRITIUM LABELLED N-MUSTARD TYPE COMPOUNDS AND A PROCESS FOR THEIR PRODUCTION ABSTRACT The present invention describes novel tritium labelled nitrogen mustard type compounds, and their aziridinium type analog, and a process for the production of same. The compounds are of value in medical research and development and also as active ingredients of pharmaceutical compositions. The compounds can be used to develop analogs of human disease states and can also be used to evaluate the mechanism of neurotransmitter regulation and function, both in vitro and in vivo.

TRANSCUTANEOUS DRUG DELIVERY SYSTEM

L'INVENTION CONCERNE UNE COMPOSITION POUR L'APPLICATION TRANSCUTANEE DE MEDICAMENTS BASIQUES DE FORTE ACTIVITE SPECIFIQUE. LE MEDICAMENT EST FOURNI EN ASSOCIATION AVEC UN ACIDE GRAS AYANT UN BAS POIDS MOLECULAIRE. ENTRE AUTRES, LE SYSTEME DISTRIBUTEUR CONVIENT POUR DES MEDICAMENTS BASIQUES CHOLINERGIQUES ET ANTICHOLINERGIQUES. LES COMPOSITIONS PEUVENT ETRE SUPPORTEES PAR UN TAMPON, UN PANSEMENT OU SIMILAIRES. L'UN DES AVANTAGES DES COMPOSITIONS DE L'INVENTION RESIDE EN CE QUE L'ON PEUT OBTENIR UN EFFET PROLONGE, AVEC UN TAUX THERAPEUTIQUE ESSENTIELLEMENT CONSTANT DU COMPOSANT ACTIF. THE INVENTION CONCERNS A COMPOSITION FOR THE TRANSCUTANEOUS APPLICATION OF BASIC DRUGS OF HIGH SPECIFIC ACTIVITY. THE MEDICINAL PRODUCT IS SUPPLIED IN ASSOCIATION WITH A FATTY ACID WITH LOW MOLECULAR WEIGHT. BETWEEN OTHERS, THE DISPENSING SYSTEM IS SUITABLE FOR BASIC CHOLINERGIC AND ANTICHOLINERGIC DRUGS. COMPOSITIONS MAY BE SUPPORTED BY A PAD, DRESSING OR THE LIKE. ONE OF THE ADVANTAGES OF THE COMPOSITIONS OF THE INVENTION IS THAT A LONG-TERM EFFECT CAN BE OBTAINED WITH AN ESSENTIALLY CONSTANT THERAPEUTIC RATE OF THE ACTIVE INGREDIENT.

Spiro(1, 3-dioxolane-4, 3') quinuclidine compounds

ABSTRACT OF THE DISCLOSURE Novel spiro (1,3-dioxolane-4,3') quinuclidine compounds of the formula

Oxathiolanes

ABSTRACT The present invention accordingly provides in one aspect, novel spiro-oxathiolane/quinuclidine compounds corresponding with the schematic structural formula (I) (I) and geometrical isomers, enantiomers, diastereoisomers, racemates and acid addition salts thereof, wherein one of Y and Z is O and the other is S(=O)n; n is 0, 1 or 2; R' and R" are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, C3-7 cycloalkyl, aryl, diarylmethylol, and alkyl substituted by at least one aryl group, provided that at least R' and R" is other than hydrogen; and each X is hydrogen, or when Y is O and Z is S(=O) simultaneously, then each X may also be selected from the group consisting of deuterium and tritium, and provided further that when each X is hydrogen, Y is O and Z is S simultaneously, then at least one of R' and R" is selected from the group consisting of alkenyl, alkynyl, cyclopropyl, cyclobutyl, cycloheptyl, hydroxyalkyl and aminoalkyl.

METHOD OF ANALOGUE FOR PREPARING THE SINGLE ISOMER OR ISOMER MIXTURE OF SPIRO- (1,3-DIOXOLAN-4,3 ') QUINUCLIDINES OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS.

ESPIRO AZA COMPOUNDS ACTING IN THE COLINERGIC SYSTEM WITH MUSCARINICA AGONIST ACTIVITY

Spiro bridged and unbridged heterocyclic compounds

Aza spiro compounds and composition acting on the cholinergic system with muscarinic agonist activity

Изобретението се отнася до спиросъединения, коитодействат активно върху централната и периферната нервна система и имат например активност на мускаринов агонист. Те са с формули в които пръстенът а заедно със спировъглеродния атом образува мостов или немостов пръстен, съдържащ един или два азотни атома в пръстена, а всеки от другите символи във формулата е определен. Изобретението се отнася още до техни фармацевтично приемливи соли, кватернернисъединения, които структурно произлизат от съединения с третичен азотен атом, енантиомери и рацемати.

OPTICAL ISOMERS OF A SPIROQUINUCLIDE DERIVATIVE.

Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments

Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them

AZA spiro compounds acting on the cholinergic system with muscarinic agonist activity, use of the same for the manufacture of a medicament, pharmaceutical composition comprising the same and chemical compound for use as a medicament

Pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds therefor

bicyclic heterocyclic spiro compounds

COMPOSTOS ESPIRO HETEROCÍCLICOS BICÍCLICOS. São descritos compostos espiro heterocíclicos bicíclicos; composições farmacêuticas compreendendo estes compostos; e métodos para o tratamento em um mamífero de doenças e condições que são susceptíveis à modulação do receptor muscarínico Ml, incluindo doença de Alzheimer, síndrome da resistência à insulina e diabete tipo 2. Outras realizações são também descritas. BICYCLIC SPIRAL HETEROCYCLIC COMPOUNDS. Bicyclic heterocyclic spiro compounds are described; pharmaceutical compositions comprising these compounds; and methods for treating a mammal for diseases and conditions that are susceptible to modulation of the muscarinic M1 receptor, including Alzheimer's disease, insulin resistance syndrome and type 2 diabetes. Other embodiments are also described.

Edge model detection and management for distributed data collection

The system includes a device database, an interface, and a processor. The device database stores a set of times and corresponding set of locations associated with a device. The interface is configured to receive a request for identification of sensor data associated with a target. The request includes a request time and/or a request location. The processor is configured to: determine a set of devices associated with the time and/or the location using the device database; provide a request to search for the sensor data associated with the target at the time and/or the location to each device of the set of devices; and receive an indication of the identification of sensor data associated with the target from an identifying device of the set of devices.

Optical isomers

Spiro agonists and antagonists of M1 and M3 muscarinic receptors for treatment of central and peripheral nervous system disorders

Disclosed is a compound of the formula (I) wherein the substituents are defined within the specification; or an enantiomer, diastereomer, racemate, tautomer, geometrical isomer, dimmer, or pharmaceutically acceptable salt thereof. Also disclosed is the use of the above compound or an enantiomer, diastereomer, racemate, tautomer, geometrical isomer, dimmer, or pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for stimulating the M1 muscarinic receptor and inhibiting the M3 muscarinic receptor.

Tritium labeled haloethylamines or aziridinium analogs thereof,their preparation and pharmaceutical compositions containing them

Compound pharmaceutical composition dextre- and levo-rotary enanciomers separated and process for the treatment of a disease of the central and peripheral nervous system in mammals

OPTICAL ISOMERS OF A SPIROQUINUCLIDE DERIVATIVE.

Drug delivery system

There is provided a composition for the transdermal application of basic drugs which have a high specific activity. The drug is provided in combination with a fatty acid having a low molecular weight. Amongst others, the delivery system is suited for cholinergic and anticholinergic basic drugs. The compositions can be supported by a pad, bandage or the like. It is one of the advantages of the compositions of the invention that a prolonged effect can be obtained, with an essentially constant therapeutic level of the active ingredient.

Crystalline polymorphs of a muscarinic acetylcholine receptor agonist

SPIRO-BROWNED AND NON-BROWNED HEROCYCLIC COMPOUNDS.

Patent IN170320B

Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor

There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more spiro compounds. Also provided are pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.

Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor

There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more Spiro compounds. Also provided and pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.

Optical isomers of a spiroquinuclidine derivative.

V.90 over all-digital connections

A method of forming a V.90 connection on an all digital connection. The method includes transmitting a request to connect from a digitally connected client modem (28) to a digitally connected server modem (24) and transmitting, by the client modem (28) to the server modem, a message requesting to form a V.90 connection, identifying the digitally connected client modem (28) as an analog connected modem.

Crystalline polymorphs of a muscarinic acetylcholine receptor agonist

Pharmaceutical compositions containing aza spiro compounds acting on the cholinergic system with muscarinic agonist activity

Spiro-oxathiolane / quinuclidine compounds, compositions containing them and their use in the preparation of a pharmaceutical composition

ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE SPIRO-OXATATIOLAN / KINUCLIDE COMPOUNDS.

FREQUENCY REQUIREMENT FOR THE PREPARATION OF 2-SUBSTITUTION SPYRO (1,3-DIOXOLAN-4,3 ') KINUCLIDINER MED KOLINERGISK EFFEKT

Stable operation of media gateway

Spiro bridged and unbridged heterocyclic compounds

AZA spiro compounds that act on the cholinergic system of muscarinic agonist activity

Spiro bridged and unbridged heterocyclic compounds

Compounds (I) and (II), including enantiomers, racemates and acid addition and quaternary salts, are for treating diseases of the central and peripheral nervous system, (see formula I and II) wherein in formula (I) Q is (CH2)m or C(CH3)2 attached to the 1',4' or 1',5' positions of the six-membered ring (m = 1, 2 or 3.) and in formula (II) Q is two hydrogen atoms, (CH2)m or C(CH3)2 (m = 1, 2 or 3) and n and p are each independently 0, 1, 2 or 3, provided that n + p = 2-3; R° is hydrogen, methyl or OH; (see formula III) is (see formula IV), (see formula V), (see formula VI or VII) R and R' are independently H, NH2, NH-C1-6-alkyl, N(C1-6-alkyl)2, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7- cycloalkyl, C1-6-alkyl substituted by 1-6 halogen atoms, HO- C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkoxy-C1-6-alkyl, carboxy-C1-6-alkyl, (C1-6-alkoxy)carbonyl-C1-6-alkyl, amino-C1-6-alkyl, mono-(C1-6-alkyl)amino-C1-6-alkyl, di-(C1-6-alkyl)amino-C1-6-alkyl, 2-oxo-pyrrolidin-1-yl-methyl, Ar, di(Ar)methylol, or (Ar)1-2C1-6 alkyl, or R' may be C1-6-alkanoyl or Arcarbonyl; and Ar denotes Ph optionally substituted by 1-3 of halogen, C1-6-alkyl, C1-6-alkoxy and GF3, subject to certain provisos.

Spiro-compounds and pharmaceutical composition containing the same

The invention relates to the spiro-compounds, to their pharmaceutically acceptable salts, to their enantiomers and racemates as well as to the quaternary compounds structurally derived therefrom, said compounds having a tertiary nitrogen atom, the spiro-compounds containing a 5-component part, having a spiro-link to the carbon atom and, simultaneously, to a carbon atom, to a saturated cyclic system, containing a nitrogen atom, and to a pharmaceutical composition therewith.

Method and apparatus for echo cancellation using a line card

A method of signal-correction. The method includes determining, by a line-card, in accordance with a modem training method, signal correction parameter values for signals transmitted on a connection passing through the line-card, and performing signal correction of the signals transmitted on the connection, by the line-card, using the determined signal correction parameter values.

Modem relay over packet based network

Secure modem transmission

A method of access control to a protected remote access server. The method includes receiving signals transmitted on a modem connection, determining in the physical layer whether the received signals include predetermined identification signals, and allowing the modem connection to be established with the protected remote access server only if the received signals include the predetermined identification signals.

Analogifremgangsmaade til fremstilling af 2,2-diphenyl-spiro-(1,3-dioxolan-4,3')quinuclidin eller farmaceutisk acceptable syreadditionssalte deraf

Oxothiolane und derivate, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als arzneimittel

Optische isomere von einem spirochinuclidinderivat.

Sistema di somministrazione di farmaci.

Crystalline polymorphs of a muscarinic acetylcholine receptor agonist

Provided are novel crystalline forms of a spiro-compound which acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are described which have favorable properties in pharmaceutical manufacture. Also provided are methods to prepare said crystalline polymorphs, and to convert them into each other as well as methods for preparing medicaments containing the same which are suitable for use in the treatment of diseases and disorders that respond to modulation of the muscarinic acetylcholine receptor.

Verteiltes modem

Modem-relais über einen paketbasierten netzwerk

Secure modem transmission

A method of access control to a protected remote access server. The method includes receiving signals transmitted on a modem connection, determining in the physical layer whether the received signals include predetermined identification signals, and allowing the modem connection to be established with the protected remote access server only if the received signals include the predetermined identification signals.

Crystalline Polymorphs of a Muscarinic Acetylcholine Receptor Agonist

Provided are novel crystalline forms of a spiro-compound which acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are described which have favorable properties in pharmaceutical manufacture. Also provided are methods to prepare said crystalline polymorphs, and to convert them into each other as well as methods for preparing medicaments containing the same which are suitable for use in the treatment of diseases and disorders that respond to modulation of the muscarinic acetylcholine receptor.

Modem relay over packet based network

A method of performing a negotiation session on a modem connection. The method includes receiving a plurality of negotiation signals from the source modem, by a first gateway, forwarding at least some of the received negotiation signals from the first gateway to a second gateway, over a packet based network, receiving, by the first gateway, responses to the forwarded negotiation signals from the second gateway, forwarding the responses from the second gateway to the source modem, by the first gateway, and transmitting from the first gateway to the source modem, response signals to at least some of the received negotiation signals, without receiving a response to the at least some of the signals from the second gateway.

Modem-relais über einen paketbasierten netzwerk

[UNK]

Quinuclidinderivater

Quinuclidinderivater, fremgangsmåde til fremstilling heraf samt farmaceutisk præparat indeholdende disse

Shirt.

Improvements in Loom Pickers

Bag

Distributed modem

A method of transmitting data bits over a modem connection. The method includes receiving a first stream of data bits, by a first modem, performing a first set of one or more communication tasks on the first stream of bits, by the first modem, so as to generate a second stream of bits, modulating the second stream of bits, by the first modem, so as to form a modulated signal, transmitting the modulated signal from the first modem to a second modem, demodulating the modulated signal by the second modem, so as to form a third stream of bits, performing on the third stream of bits, a second set of zero or more communication tasks, including a different number of tasks than the first set of tasks, so as to form a fourth stream of bits, and transmitting the fourth stream of bits to a communication unit over a packet based network.

Distributed modem

A method of transmitting data bits over a modem connection. The method includes receiving a first stream of data bits, by a first modem, performing a first set of one or more communication tasks on the first stream of bits, by the first modem, so as to generate a second stream of bits, modulating the second stream of bits, by the first modem, so as to form a modulated signal, transmitting the modulated signal from the first modem to a second modem, demodulating the modulated signal by the second modem, so as to form a third stream of bits, performing on the third stream of bits, a second set of zero or more communication tasks, including a different number of tasks than the first set of tasks, so as to form a fourth stream of bits, and transmitting the fourth stream of bits to a communication unit over a packet based network.

Sign stretcher

Improvements in or relating to Couches or Sofas.

24,569. Fisher, A. Nov. 21. Sofas; bedsteads.-The bottom b and head a are hinged so as to be capable of turning outwards as in Fig. 1. The part b is then supported by the drawer f, which is used to contain the bedding. The strap i supports the head a. The scroll h may be fitted with a secret drawer to contain money &c.

Auf das cholinerge system mit muscarin agonisticher aktivität wirkende aza-spiro- verbindungen

Ueberbrückte und nicht-überbrückte heterocyclische spiroverbindungen